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Background: Global gene expression profiling can provide insight into the underlying pathophysiology of disease
processes. Kawasaki disease (KD) is an acute, self-limited vasculitis whose etiology remains unknown. Although the
clinical illness shares certain features with other pediatric infectious diseases, the occurrence of coronary artery
aneurysms in 25% of untreated patients is unique to KD.
Methods: To gain further insight into the molecular mechanisms underlying KD, we investigated the acute and
convalescent whole blood transcriptional profiles of 146 KD subjects and compared them with the transcriptional
profiles of pediatric patients with confirmed bacterial or viral infection, and with healthy control children. We also
investigated the transcript abundance in patients with different intravenous immunoglobulin treatment responses
and different coronary artery outcomes.
Results: The overwhelming signature for acute KD involved signaling pathways of the innate immune system.
Comparison with other acute pediatric infections highlighted the importance of pathways involved in cell motility
including paxillin, relaxin, actin, integrins, and matrix metalloproteinases. Most importantly, the IL1β pathway was
identified as a potential therapeutic target.
Conclusion: Our study revealed the importance of the IL-1 signaling pathway and a prominent signature of innate
immunity and cell migration in the acute phase of the illness.Introduction
Kawasaki disease (KD) is a self-limited vasculitis of un-
known etiology that predominantly affects children aged
younger than 5 years [1]. The incidence of the disease var-
ies widely among different populations from a high of 240
in Japan to five in Norway per 100,000 children aged
under 5 years [2,3]. According to the current paradigm,
KD is an inflammatory process triggered in genetically
susceptible children following exposure to a stimulus that
may be a common antigen or infectious agent. The in-
flammation associated with KD affects the arterial wall
and leads to coronary artery aneurysms (CAA) in 25% of
untreated KD children [4], making KD the most common
cause of acquired heart disease in children in developed
countries [5]. Timely diagnosis is critical for treatment* Correspondence: Hibberdml@gis.a-star.edu.sg; jcburns@ucsd.edu
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unless otherwise stated.with intravenous immunoglobulin (IVIG) to be effective
in reducing aneurysm rates to approximately 5% [6]. How-
ever, IVIG resistance, defined as the persistence or recru-
descence of fever, has been widely reported with rates
varying from 10% to 30%, and these patients are at higher
risk of CAA formation [6-8]. Previous studies have exam-
ined gene expression profiles and described KD-specific
signatures, but these studies have had limited power due
to small sample size [9,10]. The present study of a large
KD cohort defines the global gene expression signatures
of acute KD, aneurysm formation, and resistance to ther-
apy with the identification of potential new therapeutic
targets.
Methods
Subjects
Kawasaki disease: patients diagnosed with KD had fever
for at least 3 days but not more than 10 days, and met at
least four of five clinical criteria for KD (rash, conjunc-
tival injection, cervical lymphadenopathy, oral mucosald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teria and coronary artery abnormalities documented by
echocardiogram [6]. Whole blood RNA was collected in
PAXgene tubes during the acute phase, prior to IVIG ad-
ministration, from 146 KD subjects, and after the resolution
of the acute illness and after the erythrocyte sedimentation
rate (ESR) decreased to <40 mm/h and the C-reactive pro-
tein (CRP) level decreased to <1.0 mg/dl (convalescent
phase, illness day 19 to 2,230) in 131 subjects. (Additional
file 1: Figure S1A) Complete blood counts and other clinical
laboratory testing were performed on the same blood sam-
ple used for transcript analysis. Coronary artery dimensions
were described by the variable Zmax, which was defined as
the maximal Z score (standard deviation units from the
mean) of the internal diameter of the left anterior descend-
ing and right coronary arteries normalized for body surface
area during the first 6 weeks after illness onset. IVIG treat-
ment resistance was defined as persistent or recrudescent
fever at least 36 h after the end of their IVIG infusion. All
patients were enrolled at Rady Children?s Hospital San
Diego after obtaining written parental informed consent and
patient assent as appropriate. The study protocol was con-
ducted in accordance with the declaration of Helsinki and
reviewed and approved by the University of California - San
Diego Institutional Review Board.
Gene expression microarray
RNA expression was analyzed according to the detailed
protocol as previously published [11]. In brief, whole
blood (2.5 mL) was collected directly into PAXgene RNA
tubes (Qiagen, Sussex, UK). RNA extraction was per-
formed using Paxgene RNA kits (Qiagen). Biotinylated
amplified cRNA was generated by in vitro transcription
(IVT) technology using Illumina TotalPrep RNA Amplifi-
cation Kit (Ambion, Inc., Austin, TX, USA) according to
the manufacturer ? s instructions. After purification, 2 μg of
cRNA was hybridized to an Illumina HumanRef-12 V4
BeadChip (containing probes for more than 47,000 gene
transcripts) at 55?C for 18 h following the manufacturer ? s
instructions (Illumina, Inc., San Diego, CA, USA). This
was followed by washing, blocking, and streptavidin-Cy3
staining steps. Finally, the chip was scanned with an
Illumina Bead Array Reader confocal scanner and
checked using Illumina QC analysis. Background sub-
tracted raw gene expression intensity data were
exported from Genome studio and used for further ana-
lysis. All the raw and normalized gene expression data
are available at the GEO public database. The accession
number is GSE63881.
Validation by reverse transcriptase-polymerase chain
reaction
To validate the microarray results, transcript abundance
levels were measured by reverse transcriptase-polymerasechain reaction (RTPCR) for IL1B (ABI, Hs01555410_m1),
IL1R1 (ABI, Hs00991002_m1), IL1R2 (ABI, Hs010303
84_m1), IL1RAP (ABI, Hs00895050_m1), and IL1RN
(ABI, Hs00893626_m1), for a new patient cohort of 20
KD subjects using acute and convalescent paired whole
blood RNA samples (PAXgene tubes). Controls (n = 10)
were age-similar healthy children undergoing minor elect-
ive surgery (Additional file 2: Table S5). Relative abun-
dance of the target transcripts was normalized to the
expression level of the housekeeping gene, TATA box-
binding protein-associated factor, RNA polymerase I, B
(TAF1B), as previously described [10].Reference datasets
Gene expression data (raw data) from whole blood from
children with confirmed bacterial infections, viral infec-
tions, and healthy controls were downloaded from pub-
lished papers. From GSE40396 study [12], we retrieved
gene expression data for 22 healthy children who were
afebrile and tested negative for viral infections, and
from eight, 11, six, 10, and eight children infected with
bacteria, adenovirus, enterovirus, human herpes virus
(HHV)-6 virus, and rhinovirus, respectively. Expression
data from children with adenovirus, enterovirus, and
HHV-6 were combined to form a pan-virus group of 27
patients. Expression profiles from rhinovirus-infected
patients were not included in the analysis because these
patients were afebrile when the samples were collected
and rhinovirus is not generally associated with systemic
signs of inflammation including fever. (Additional file 1:
Figure S1B). From dataset GSE42026 [13], we retrieved
expression data for 33 healthy pediatric control subjects,
18 subjects with Gram-positive bacterial infection (of
whom five were co-infected with viruses), 19 subjects
with influenza 09/H1N1 infection only, and 22 subjects
infected with respiratory syncytial virus (RSV) only
(Additional file 1: Figure S1C).Data normalization
All datasets were normalized by using R [14]. First, the raw
data were log10 transformed before Z score transformation
was performed [15]. Z score was calculated within each
sample by subtracting the overall mean gene intensity from
the raw intensity signal for each gene. After that, these data
were divided for the standard deviation of all of the mea-
sured intensities using the following formula:
Zscore ? intensityG ‐ mean intensityG1 ? Gn
SD G1? Gn? ?
Where G is any gene on the microarray and G1? Gn
represents the aggregate measure of all of the genes.
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We used Z score (standard deviation units from the mean)
as the base value to identify differentially abundant tran-
scripts (DATs) in comparisons between any two groups of
samples. Transcripts with high Z scores were those that
were more abundant while those with low Z scores were
the less abundant [15]. Conventional fold-change calcula-
tions were not used because at low intensities, when data
are much more variable, the false discovery rate increases.
To identify DATs in each group of patients, a Z-score ratio
for each gene was calculated [16]. The Z-score ratio was
calculated by dividing the mean difference in Z score be-
tween the groups by the standard deviation of the Z score
difference across all the genes.
Zratio ? MeanZscore group1? ? −meanZscore group2? ?
SDof ZscoredifferencesG1? Gn
Where G1? Gn represents the aggregate measure of
all the genes. A Z ratio of ?1.96 is equivalent to the sig-
nificance level of P <0.05 [15].
The Z test was used as an additional method for iden-
tification of DATs where δ2 is the standard deviation of
gene i in group1 or group 2, n is the sample size in each
group.
Ztest ? MeanZscore group1? ? −meanZscore group2? ?ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
δ2
n1
? δ2n2
q
DATs were defined as follows: (1) a Z ratio of ?1.96;
and (2) an adjusted Z test P value of ≤0.05 and expressed
in at least one sample.
Generalized linear model (GLM)
Because the mean yield of total RNA in acute samples
were significantly higher than in the convalescent sam-
ples, probably due to the differences in the total number
of white blood cell counts in the blood samples, we de-
cided to use absolute cell number in acute and convales-
cent KD subjects as a covariant in a generalized linear
model (GLM) when comparing their transcriptome
profiles.
Gij ? β0 ? β1Covariates ? β2Group
Where Gij denotes transformed-Z score normalized ex-
pression value for individual i at day j; Covariates were the
absolute number of lymphocytes, neutrophils and mono-
cytes and Group was either 1 for acute or 0 for convales-
cent. Benjamini-Hochberg multiple testing correction was
applied. DAT were defined to have corrected P value
<0.05 and fold-difference >1.5.
Ingenuity pathway analysis
DATs were analyzed by ingenuity pathway analysis (IPA)
[17]. The IPA database contains canonical pathways andfunctional gene relationships expertly curated from the
literature which helps in understanding disease pro-
cesses by identifying key biological functions and novel
molecular networks. DAT lists were cross-referenced
against this database to identify enriched pathways asso-
ciated with the clinical conditions. Significant canonical
pathways were defined as having a Fisher ? s exact test P
value ≤0.05 (B-H correction).
Summary of samples and datasets for analysis
We successfully analyzed 146 samples at the acute phase
and 131 samples at the convalescent phase from the KD
subjects. Of these 146 patients, 16 (11%) had coronary
artery aneurysms (CAA), 30 (20.5%) had transiently di-
lated CA, and 100 (68.5%) had normal CA (Zmax <2.5).
For the analysis of treatment response, the six patients
treated with IVIG plus infliximab for cardiac indications
were excluded. Of the remaining 140 patients, 110 (79%)
were responsive to IVIG treatment and 30 (21%) were
resistant. Of these 30 resistant subjects, 11 (30.5%) de-
veloped CAA (Additional file 1: Figure S1A).
Identification of differentially abundant transcripts
There were 39,390 probes that were common in all data-
sets and they were used for identification of DATs in
each subject group.
Acute vs. convalescent KD subjects
The baseline characteristics of these patients are sum-
marized in Additional file 2: Table S1. Gene expression
profiles from 146 acute KD patients were contrasted
with those from 131 convalescent patients without tak-
ing into account the difference in the cell numbers be-
tween them. From the total of 39,390 probes, 2,414 were
differentially expressed (adjusted P value ≤0.05, 1.96 < Z
ratio < -1.96) between the acute and convalescent KD
subjects. Of the 2,414 probes, 1,541 probes were more
abundant 873 probes were less abundant in acute sam-
ples. Using the GLM model to take into account differ-
ences in peripheral blood cell numbers, we identified
1,083 DATs between acute and convalescent subjects.
Among these 1,083 DATs, 264 were less abundant and
819 transcripts were more abundant in acute samples.
Infectious disease control subjects vs. healthy children
From the GSE40396 dataset, we identified 2,395 tran-
scripts (adjusted P value ≤0.05, 1.96 < Z ratio < -1.96) that
were more (1,053) or less (1,342) abundant in children
infected with adenovirus, enterovirus, or HHV-6 in com-
parison with the healthy controls. Similarly, we identified
2,233 DATs (933 more and 1,300 less abundant) in
bacteria-infected patients compared to healthy controls.
In comparison with the healthy controls in GSE42026
dataset, we identified 2,175 (adjusted P value ≤0.05, 1.96 <
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DATs in influenza 09H1N1-infected patients, 1,823 (826
more, 987 less abundant) DATs in RSV-infected patients
(adjusted P value ≤0.05, 1.96 < Z ratio < -1.96), and 2,327
DATs (1,007 more and 1,320 less abundant) in children
infected with a bacterial pathogen (adjusted P value ≤0.05,
1.96 < Z ratio < -1.96).
Results
Gene ontology analysis
Acute vs. convalescent KD
Because we had detailed clinical laboratory data from
our KD subjects concurrent with the whole blood RNA
samples, we assessed whether cell subtype numbers af-
fected gene ontology. The difference in lymphocyte, neu-
trophil, and monocyte numbers between acute and
convalescent samples were taken into account using the
GLM model. Fewer DATs (1,083 vs. 2,414) were identi-
fied when cell numbers were taken into account and
gene ontology analysis for the more abundant transcripts
at acute stage (819 and 1,541) identified 110 and 183 sig-
nificant pathways in the GLM and Z test, respectively.
Among these pathways, 95 were common to both ana-
lyses. Gene ontology analysis for the less abundant tran-
scripts at the acute stage (264 and 873) identified 17 and
47 significant pathways in the GLM and Z test, respect-
ively, of which 15 pathways were common. Although
there were significant differences in the numbers of
DATs between the GLM and Z test methods, there was
significant overlap between the key canonical pathways
identified by either method. While the cell count num-
bers are likely to be proportional to any specific immune
cell type, we cannot rule out the possibility that small
specific subsets of immune cells may have a large effect
on these results. However, the large overlap suggests that
these effects are likely to be small. Prominent among the
genes driving the common upregulated pathways (Figure 1A)
were genes involved in IL-1 signaling and the innate im-
mune response. Prominent among the common downregu-
lated pathways (Figure 1B) were genes in the family
encoding for ribosomal proteins and T-cell related genes in-
cluding CD3, LCK, and HLA Class II antigens.
IVIG treatment response
The baseline characteristics of IVIG-responsive and resist-
ant subjects are summarized in Additional file 2: Table S2.
To identify transcripts that distinguish IVIG-responsive
and IVIG-resistant subjects, we used the Z test to compare
the acute expression profiles of subjects who were respon-
sive (n = 110) and resistant to IVIG treatment (n = 30). We
identified 137 transcripts that were differentially abundant
between the IVIG-responsive and IVIG-resistant subjects.
Pathway analysis for these 137 transcripts showed that most
of the pathways were involved in T cell-related responses(Figure 2). Transcripts that were involved in these path-
ways included CD3E, CD4, ITGA5, ZAP70, NFkB2, LCK,
PAFAH1B3, and TNFSF13B. When stratifying genes by
the magnitude of the fold-difference, the top DATs were
matrix metalloproteinase-8 (MMP-8), ankyrinD22, carci-
noembryonic antigen cell adhesion molecule 1 (CEACA
M1), Fructose-2,6 biphosphatase 2 (PFKB2), and hapto-
globin (HP) with higher fold-difference in transcript abun-
dance in subjects with resistance to IVIG (Additional
file 2: Table S3).Coronary artery outcomes
The baseline characteristics of subjects with normal CA
and with CAA are summarized in Additional file 2:
Table S4. We chose to analyze only the extreme pheno-
types of normal and CAA + without including the tran-
siently dilated subjects. The Z test comparison between
subjects with normal CA (n = 100) and those who devel-
oped CAA (n = 16) found only four DATs (ASPRV1,
CYP26B1, TRANK1, and NKX3-1) which were all downreg-
ulated in CAA+ compared to normal CA. The cytochrome
P450 oxidase, CYP26B1, had the greatest fold-difference and
was suppressed in subjects who developed coronary artery
abnormalities compared to subjects with normal arteries
(P= 0.003) (Figure 3).Comparison of KD with pediatric infectious diseases
More and less abundant transcripts in each condition
were analyzed using IPA. From the pathway analysis, ca-
nonical pathways that were common for all conditions
or specific for KD were identified using pathway com-
parison analysis. From the upregulated transcripts, there
were 19 pathways that were over-represented in all dis-
ease conditions (Figure 4A). The majority of them were
involved in host immune response (Interferon Signaling,
TREM1 signaling, Toll-like receptor (TLR) signaling,
acute phase response signaling, complement system) and
cytokine responses (IL1, IL6, IL8, IL10, IL12, and IL22).
Interferon signaling was strongly over-represented in pa-
tients infected with viral pathogens, but notably low for
the KD subjects (Figure 4A). There were 13 pathways
that were common to KD and viral infections including
NF-kB signaling, granulocyte adhesion and diapedesis,
and dendritic cell maturation (Figure 4B). There were
only eight pathways that were shared between KD and
bacterial infection patients (Figure 4C), with the most
significant being coagulation system, IFG-1 signaling,
and extrinsic prothrombin activation pathways. There
were 47 pathways that were only over-represented in KD
subjects (Figure 4D). Genes related to cell migration and
trafficking (paxillin, relaxin, actin, integrins, MMPs) and
signal transduction (MAP kinases and phosphatases)
were the leading DATs.
Figure 1 Overlapping differentially expressed pathways in acute vs. convalescent KD determined by both GLM and by Z test. (A) Top
15 upregulated pathways in acute KD were highly involved in innate responses; (B) 15 downregulated pathways in acute KD were highly
involved in host protein synthesis and T cell responses. The P values were determined using Fisher ? s Exact Test with Benjamini-Hochberg multiple
testing corrections. Although there was a large difference in the number of DATs, the most significant pathways were highly similar between the
two methods.
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(Trem1 signaling, Hepatic fibrosis, and IL-10 signaling)
and the other groups were the abundance of transcripts
related to the activation of the Nlrp3 inflammasome, in-
cluding Il-1 and caspase-1 related transcripts (Figure 5).
The key genes in IL1 pathway IL1B, IL1R1, IL1R2,
IL1RAP, and IL1RN were validated using qPCR in KD
patients (Figure 6). Other key transcripts in these path-
ways included TLRs, matrix metalloproteinases, NFkB sig-
naling molecules, and IL-10 (Figure 7, Additional file 2:
Table S6).We identified 20 pathways that were over-represented
in the less abundant transcript group and were shared by
all disease conditions (KD acute vs. conv., other groups vs.
healthy controls). T cell-related response pathways (iCOS-
iCOSL Signaling in T Helper Cells, Calcium-induced T
Lymphocyte Apoptosis, CD28 Signaling in T Helper Cells,
PKCθ Signaling in T Lymphocytes, and T Cell Receptor
Signaling) and NK cell signaling were predominant among
these 20 pathways. In addition, IL4, IL2, and C chemokine
receptor (CCR) signaling pathways were also prominent
(Figure 8A). EIF2 signaling was the only pathway that was
Figure 3 Comparison of transcripts from KD subjects with normal coronary arteries and those with coronary artery aneurysms by Z test
revealed only four DATs: (A) ASPRV1, (B) CYP26B1, (C) TRANK1, and (D) NKX3-1 * P value <0.05.
Figure 2 Gene pathways that were up-regulated in patients who were responsive to IVIG treatment in comparison with IVIG-resistant patients.
DATs were derived from Z test. The Y axis depicts the -log10 of BH corrected P value which identified by Fisher? s exact test. The majority of the pathways
were T cell, NK cell-related response.
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Figure 4 Comparison of the gene pathway analysis of upregulated pathways in each group of patients determined by the Z test. (A) Pathways
that were upregulated (KD acute vs. conv., other groups vs. healthy controls) and shared among KD, viral, and bacterial infection groups (see Additional file 2:
Table S5). (B) Pathways that were shared between KD and viral infections. (C) Pathways shared by KD and bacterial infections. (D) Pathways that were
specifically upregulated in KD patients and. These over-represented pathways were identified using IPA database. The numbers in each box represents the
-log10 P value (BH corrected) identified by Fisher? s exact test. The colors represent the strength of association with pathways with dark red designating the
highest and white the lowest level of association.
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the highest levels of suppression seen for KD and influenza
H1N1-infected subjects (Figure 8B). There were no path-
ways that were uniquely shared between KD and bacteria-
infected subjects. Granzyme A signaling and lipoate salvage
and modification were the pathways that were specifically
downregulated in KD subjects only (Figure 8C). These path-
ways contain genes related to cytotoxic T cell signaling and
apoptosis (Figure 9, Additional file 2: Table S7).
Discussion
We describe here the similarities and differences between
the host transcriptional profiles of acute and convalescent
KD subjects and profiles of children with acute bacterial
and viral infections. There were several upregulated path-
ways uniquely over-represented in KD subjects including
paxillin signaling, G-protein coupled receptor signaling,
triacylglycerol and relaxin signaling. The paxillin signaling
pathway, which includes α-smooth muscle actin (ACTA2),
actinin, paxillin, talin, and integrins, is important for creatingcell to extracellular matrix focal adhesions during myofi-
broblast transformation and cell migration [18,19]. We
also found increased transcript abundance for pathways
that oppose myofibroblast formation, including the relaxin
signaling pathway, which was uniquely increased in acute
vs. convalescent KD. Relaxin prevents cardiac fibroblast-
myofibroblast transition via Notch-1-mediated inhibition
of TGF-β/Smad3 signaling leading to reduction of α-SMA
synthesis and inhibition of extracellular focal adhesion for-
mation [11]. This is of interest because of the proposed
role in KD of endothelial/epithelial-to-mesenchymal tran-
sition leading to myofibroblast formation. These cells are
thought to migrate into the arterial wall and myocardium
where they recruit pro-inflammatory cells that contribute
to tissue damage [20,21]. Increased expression of genes
that block myofibroblast migration may represent an
adaptive host response to limit the pathogenic role of
these cells.
The most dramatic finding was the marked upregula-
tion in acute KD subjects of pathways involved with the
Figure 5 IL1signaling pathway was the key upregulated pathway in acute KD. (A) Transcripts involved in IL1 signaling pathways were more
abundant in acute KD; DATs between acute and convalescent KD samples are highlighted in red. (B, C) IL1R1 and IL1RAP were differentially
expressed only in acute vs. convalescent KD but not in other diseases. **P value <0.01.
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to subjects in the convalescent phase of KD. Although
many of the same pathways were upregulated across all
disease groups, the magnitude varied with the KD sub-
jects having greater elevation of selected transcripts in
the IL1, IL10, and NF-kB signaling pathways. Pathways
with genes involved in IL1 signaling were more abun-
dant in all conditions; however, the key receptors in the
pathway were only upregulated in KD patients (IL1R,
IL1RAP). IL1R and IL1RAP (IL-1 receptor accessory
protein) are expressed on the cell surface where they
directly bind IL1, which in turn activates the signaling
cascade. All of the top five pathways for KD subjects
prominently featured IL-1 signaling molecules including
IL-1R, IL-1RAP, IL-1R2 (IL-1 decoy receptor), andIL1RN (IL1 receptor antagonist), thus suggesting that
IL-1 signaling plays a critical role in KD pathogenesis.
We also observed that while the pro-inflammatory IL1
pathway is activated, the anti-inflammatory IL10 path-
way is also activated (STAT3, SOCS3) as a negative
regulator of IL-1β synthesis, signaling, and bioavailability
[22]. The IL1 receptor antagonist anakinra has been
used to treat a severe KD patient who was unresponsive
to IVIG [23]. Our observations suggest that the IL-1 sig-
naling pathway is a key mediator in the pathogenesis of
KD and may represent an important therapeutic target.
T cell and NK cell-related signatures in the peripheral
blood were attenuated across all disease groups with re-
duced expression of genes involved in antigen presenta-
tion through MHC Class II, T cell signaling, and protein
Figure 6 Transcript abundance levels of IL1B, IL1R1, IL1R2, IL1RAP, and IL1RN were measured in a new cohort of KD subjects (n = 20)
and controls (n = 10) by reverse transcriptase-polymerase chain reaction (RTPCR). The relative abundance of these genes were normalized
against the expression level of the house keeping gene (TAF1B). qPCR results showed that these key IL1 genes were highly abundant in acute
phase of KD patients in comparison with the convalescent phase and with the controls.
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infected children in the dataset used in the present study,
the signature of decreased protein synthesis for KD sub-
jects was driven by reduced expression of ribosomal pro-
teins without increased expression of genes known to
inhibit protein synthesis (for example, EIFAK2) [13]. Both
the KD and the H1N1-infected subjects had marked sup-
pression of the EIF2 pathway contributing to the suppres-
sion of protein synthesis. Whether the suppression of hostFigure 7 Significantly upregulated genes in the top 12 pathways com
pathway were highlighted in red boxes.protein synthesis in KD subjects is an adaptive response
to reduce pathogen-directed protein synthesis or whether
this represents a pathogenic suppression of host protein
synthesis by the ?KD agent? is unknown. What is clear is
that transcript abundance of genes critical for protein syn-
thesis is markedly reduced in acute KD subjects.
Variation in global gene expression patterns related to
IVIG response has been reported by several groups
[9,24-27]. In our study of the largest sample size everparing acute vs. convalescent Kawasaki disease. DATs in each
Figure 8 Comparison of the downregulated pathways. Similar to the upregulated pathway analysis, these pathways were identified by comparing the
gene lists with the IPA database. (A) Common pathways those were downregulated in all groups of patients (see Additional file 2: Table S6). (B)
Downregulated pathways shared by KD and viral infections and (C) downregulated KD-specific pathways. The numbers in each box represent
the -log10 P value (BH corrected) identified by Fisher? s exact test. The colors represents the strength of association with pathways with dark green
designating the highest and white is the lowest level of association.
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IVIG treatment had more abundant transcripts in path-
ways involved in T and NK cell responses. Transcripts
that were involved in the majority of these pathways
were CD3E, CD4, TNFRSF3B, SERPINA1, MME, and
IRF4. Among the top DATs when stratified by the mag-
nitude of the fold-difference between acute blood sam-
ples from IVIG responsive and resistant subjects were
MMP-8, CEACAM1, and PFKB2. Transcripts for both
MMP-8 and CEACAM1 were elevated in IVIG-resistant
KD subjects in three previous studies [10,24,26]. MMP8
or neutrophil collagenase may be secreted by neutrophilsinfiltrating into the arterial wall that contribute to the
persistence of inflammation in IVIG-resistant KD pa-
tients [28,29]. CEACAM1 is expressed on the surface of
endothelial cells, lymphocytes, and myeloid cells, and
acts as an activation-induced co-inhibitory receptor on
T cells [30]. Expression of CEACAM1 on activated T
cells in KD patients may represent a compensatory
mechanism to decrease the pro-inflammatory response.
Alternatively, increased expression of CEACAM1 on
neutrophils is associated with delayed apoptosis, which
may be related to the observed persistence of inflamma-
tion in KD patients failing to respond to IVIG [8,13].
Figure 9 Significantly downregulated genes in the top 11 pathways comparing acute vs. convalescent Kawasaki disease. DATs in each pathway
were highlighted in red boxes.
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with KD, but its role as an intracellular regulator of gly-
colysis in cardiomyocytes and its increased expression in
the right ventricle of children with Tetralogy of Fallot
and right ventricular pressure overload is intriguing [31].
Myocarditis is a universal feature of acute KD and one
could speculate that patients with IVIG-resistance who
have a global increase in inflammation may also have
more intense myocardial inflammation leading to altered
glycolysis in cardiomyocytes [32].
Of the genes differentially expressed between the CAA
and normal CA groups, CYP26B1 had a biologically
plausible link with the inflammatory process of KD.
Cyp26b1 is a member of the cytochrome P450 system
that is expressed in many cell types including vascular
smooth muscle cells and T cells in which it acts as a
negative regulator of retinoic acid signaling. Retinoic
acid has widespread vascular effects including inhibition
of intimal proliferation and effects on differentiation of
na?ve T cells. Depending on the cytokine milieu, retinoic
acid can stimulate the differentiation of na?ve T cells to-
ward either a regulatory (Treg) or inflammatory (Th17)
phenotype [33]. KD subjects with CAA had decreased
expression of Cyp26b, which would result in increased
retinoic acid signaling and potentially increases in pro-
inflammatory CD4+ Th17 cells. Functional polymor-
phisms in Cyp26b1 have been described that modulate
gene expression and if the association of reduced
Cyp26b1 gene expression is validated in independent co-
horts of CAA vs. normal CA cohorts, then genotyping
for these variants may contribute to our understanding
of susceptibility to CAA. Gene expression for the skin
aspartic acid protease (SASPase) gene was also sup-
pressed in KD subjects with CAA. This protease plays a
key role in profilaggrin-filaggrin processing and reduced
expression in mice leads to an eczema phenotype [34]. It
is of interest that eczema is over-represented among pa-
tients with KD and perhaps genetic variants in this gene
may contribute to this phenotype [35,36]. However, the
association with CAA is unclear as expression is claimedto be limited to the skin [37]. Suppression of NKX3-1, a
homeobox-containing transcription factor that is regu-
lated by TNFα and IL1β, was also observed in CAA KD
subjects. One target of NKX3-1 is vascular endothelial
growth factor (VEGF), a protein that stimulates lymph
node lymphangiogenesis [38]. Hyperplasia of lymph
nodes that drain the posterior pharynx is a prominent
feature of acute KD. Reduced levels of NKX3-1 would
be expected to increase VEGFC signaling and lead to
lymph node enlargement, although the relationship with
CAA is unclear. TRANK1 expression was also sup-
pressed in CAA KD although little is known about the
function of this gene.
Several previous observations regarding KD gene ex-
pression are supported by the data in the present study.
The muted signature for interferon signaling was in sharp
contrast to the expression profiles for viral-infected sub-
jects, especially those infected with H1N1 [39,40]. The
low abundance of interferon and interferon-induced tran-
scripts was also observed in a study of gene expression
profiles in acute KD subjects compared to subjects with
adenovirus infection [16]. The observation was confirmed
by RT-PCR of the interferon-inducible genes MX1, ISG15,
and LY6E in an independent cohort of KD subjects [10].
Notable differences in the DAT patterns in KD observed
in the present study compared to previous reports may be
due to both the larger samples size as well as the correc-
tion for cell numbers. Polycythemia vera 1 (CD177), which
is expressed by activated neutrophils and has been previ-
ously reported as a leading DAT in KD, was not among
the top DATs in our study [27]. This is likely due to the
large difference in absolute neutrophil count between
acute and convalescent blood samples from KD subjects,
which was accounted for in our analysis with the GLM
method. Previous studies did not correct for absolute neu-
trophil count.
We recognize several strengths and weaknesses to the
present study. We have created the largest database of
DATs in KD ever assembled and this valuable resource
is now available to other investigators to mine for data
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the scope of the present study to perform RT-PCR assays
for DAT validation for all the potential targets or to meas-
ure serum levels of specific proteins. The results presented
here must therefore be viewed in the spirit of generating
hypotheses about novel pathways and proteins that must
be validated in independent cohorts. However, the large
sample size gives good statistical confidence in the results
obtained.
Conclusion
In conclusion, our study of DATs in acute and convalescent
KD whole blood samples revealed the importance of the
IL-1 signaling pathway and a prominent signature of innate
immunity and cell migration in the acute phase of the ill-
ness. Pathways predicted to both increase myofibroblast
transformation and migration and to oppose myofibroblast
formation were also upregulated in the acute disease. Signa-
tures for protein synthesis and T and NK cells were mark-
edly depressed in acute KD. Important differences from
other infectious diseases were the attenuation of an inter-
feron signature in KD vs. viral infections. IVIG responders
had increased transcript abundance for genes associated
with T and NK cells, while IVIG-resistant subjects had in-
creased transcripts for genes association with neutrophil in-
filtration and apoptosis. A novel finding related to the host
response to IVIG was the association of PFKB2, a master
regulator of cardiomocyte glycolysis, with IVIG resistance.
CAA was associated with transcripts related to eczema and
lymph node hyperplasia. Most importantly, CAA was asso-
ciated with decreased transcript abundance of CYP26b1, a
negative regulator of retinoic acid signaling, Opportunities
for translation of these observations include the use of
agents that block the IL-1 signaling pathway and agents
that stimulate the retinoic acid signaling pathway toward T
cell regulation.
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